Abstract: Provided is an unobtrusive client verification system with one verification devices having processors that are configured to receive a first request from an unverified client device, generate a random number in response to receiving the first request from the unverified client device, define a set of expressions as a browser challenge problem that evaluates to an answer specified by the random number, encrypt the answer within an answer token, provide the browser challenge problem with the answer token to the unverified client device, receive a second request with a solution to the browser challenge problem and the answer token from the unverified client device, and verify the unverified client device in response to the solution matching the answer that is decrypted from the answer token provided with the second request.

Abstract: Provided is an Adaptive Network Security System (“ANSS”) that receives a first set of network data, detects commonality in a set of parameters within the first set of network data using an unsupervised machine learning technique, and models an expected behavior based on the commonality in the set of parameters. The ANSS may determine a threat risk associated with a second set of network data based on an amount of deviation between the set of parameters from the second plurality of network data and the expected behavior, and may perform a particular action from different actions against the second set of network data in response to the set of parameters from the second set of network data deviating from the expected behavior and the threat risk.

Abstract: Provided is an unobtrusive client verification system with one verification devices having processors that are configured to receive a first request from an unverified client device, generate a random number in response to receiving the first request from the unverified client device, define a set of expressions as a browser challenge problem that evaluates to an answer specified by the random number, encrypt the answer within an answer token, provide the browser challenge problem with the answer token to the unverified client device, receive a second request with a solution to the browser challenge problem and the answer token from the unverified client device, and verify the unverified client device in response to the solution matching the answer that is decrypted from the answer token provided with the second request.

Abstract: Provided is an unobtrusive client verification system with one verification devices having processors that are configured to receive a first request from an unverified client device, generate a random number in response to receiving the first request from the unverified client device, define a set of expressions as a browser challenge problem that evaluates to an answer specified by the random number, encrypt the answer within an answer token, provide the browser challenge problem with the answer token to the unverified client device, receive a second request with a solution to the browser challenge problem and the answer token from the unverified client device, and verify the unverified client device in response to the solution matching the answer that is decrypted from the answer token provided with the second request.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a continuous process for producing a haloalkenone ether of the Formula (I) wherein R1 is C1-C6 haloalkyl, R2 is a C1-C6 alkyl or phenyl, the process comprising:—(i) reacting, in a first continuous stirred tank reactor comprising a solvent, a halide of Formula (II) wherein R1 is as previously defined and R3 is halogen, with a vinyl ether of Formula (III) wherein R2 is as previously defined, to form an intermediate compound of Formula (IV), wherein the concentration of the vinyl ether of Formula (III) in the reaction mass is 15% or less w/w; and (ii) transferring the reaction mass from the first continuous stirred tank reactor into a subsequent continuous stirred tank reactor, wherein the conditions within the subsequent reactor permit the elimination of hydrogen halide (HR3) from the intermediate compound of Formula (IV) to provide the haloalkenone ether of Formula (I).

Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a continuous process for producing a haloalkenone ether of the Formula (I) wherein R1 is C1-C6 haloalkyl, R2 is a C1-C6 alkyl or phenyl, the process comprising:—(i) reacting, in a first continuous stirred tank reactor comprising a solvent, a halide of Formula (II) wherein R1 is as previously defined and R3 is halogen, with a vinyl ether of Formula (III) wherein R2 is as previously defined, to form an intermediate compound of Formula (IV), wherein the concentration of the vinyl ether of Formula (III) in the reaction mass is 15% or less w/w; and (ii) transferring the reaction mass from the first continuous stirred tank reactor into a subsequent continuous stirred tank reactor, wherein the conditions within the subsequent reactor permit the elimination of hydrogen halide (HR3) from the intermediate compound of Formula (IV) to provide the haloalkenone ether of Formula (I).

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.

Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.

Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Abstract: The present invention relates to a unique and novel PC based software solution interface with embedded DSP based Online UPS system. In the present invention, a single DSP is used to control the Online UPS and further to communicate with the PC based software which enables direct transfer of real-time values of parameters to the PC. Such direct transfer of data is accomplished through a dedicated communication protocol that is implemented both inside the DSP chip, and in the monitoring software. As the DSP can process the information very fast, the processing of all the data can be completed by the DSP and transferred to the monitoring software. The requisite provisions are made in the DSP embedded chip inside the Online UPS system so as to receive the data from the Monitoring system and correspondingly change the Output voltage/Frequency, Battery Low level and battery high level.